# Patent Watch: Smoore Targets Controlled Cannabinoid

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-smoore-targets-controlled-cannab-2026-10-09/
> **Published:** 2026-10-09T09:21:46-04:00 | **Last Modified / Clinically Audited:** 2026-10-09T09:21:46-04:00
> **Clinical Summary:** The application’s title identifies cannabis-based aerosol-generating substrates, articles, systems, and methods intended to control cannabinoid delivery th

---

PATENT WATCH
 US20260206833A1
 
 

# Patent Watch: Smoore Targets Controlled Cannabinoid Aerosol Delivery

 
 **Assignee:** Smoore International Holdings Limited
 **Inventors:** Chen SONG, Jianguo Wang, Ying Zhang, Shengsheng Liu, Meng Huang, Wenjing Wei, Ying Wei, Yichen Li
 **Published:** 2026-07-23
 
 

 
 Invention Summary & Claims
 

The application’s title identifies cannabis-based aerosol-generating substrates, articles, systems, and methods intended to control cannabinoid delivery through inhalation. The available disclosure does not identify specific cannabinoid active pharmaceutical ingredients, excipients, substrate compositions, or dose-control mechanisms, limiting assessment of formulation novelty and technical differentiation.

 

 

## Clinical Perspective & Therapeutic Significance

 

More reproducible inhaled cannabinoid delivery could help patients and clinicians titrate treatment, but delivered dose and systemic exposure would require testing across devices, formulations, and inhalation patterns. The available disclosure establishes neither improved bioavailability nor a validated therapeutic indication, and respiratory safety would depend on aerosol chemistry, operating conditions, and exposure.

 

## Intellectual Property & Market Landscape

 

Smoore International Holdings Limited is an established aerosol and vaping technology company, positioning this application within its broader delivery-platform business. Compared with conventional cannabis flower and vape cartridges, the proposed distinction is controlled cannabinoid delivery, although the available information does not establish superiority over existing products or identify enforceable claim boundaries.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260206833A1)](https://patents.google.com/patent/US20260206833A1/en).
 

 
 Editorial Commentary
 

This application addresses an important challenge in inhaled cannabis: making cannabinoid exposure more predictable. Its clinical significance will depend on demonstrated dosing consistency, respiratory safety, and patient outcomes, not the patent filing alone.

 

 
 

### Frequently Asked Questions

 
 Could this technology make inhaled [cannabis dosing](https://cedclinic.com/cbd-gummies-pharmacokinetics-effects-evidence-use/) more predictable?
 That is the stated direction of the application, but reliable dosing has not been demonstrated in the available disclosure. Device output, inhalation technique, and cannabinoid absorption can each affect the dose a patient receives.

 Does this patent application mean the technology has passed clinical trials?
 No. A published patent application describes an intellectual property position, not proof of clinical efficacy, safety, regulatory authorization, or a granted patent.

 When could patients obtain a product based on this application?
 No product launch or therapeutic availability timeline is established by the available disclosure. Availability would depend on development, testing, commercialization, and applicable jurisdiction-specific requirements.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).